(Q37911726)

25 August 2017

1 reference

title

Inflammatory neurological disease in patients treated with tumor necrosis factor alpha inhibitors (English)

1 reference

25 August 2017

0 references

0 references

Andrew J Solomon

1

1 reference

25 August 2017

Rebecca I Spain

series ordinal

2

1 reference

25 August 2017

Michael C Kruer

series ordinal

3

1 reference

25 August 2017

Dennis Bourdette

series ordinal

4

1 reference

25 August 2017

publication date

3 August 2011

1 reference

Multiple Sclerosis Journal

25 August 2017

published in

1 reference

25 August 2017

volume

17

1 reference

25 August 2017

issue

12

1 reference

25 August 2017

page(s)

1472-1487

1 reference

Demyelinating and neurologic events reported in association with tumor necrosis factor alpha antagonism: by what mechanisms could tumor necrosis factor alpha antagonists improve rheumatoid arthritis but exacerbate multiple sclerosis?

25 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F1352458511412996

Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511412996

Guillain-Barré and Miller Fisher syndromes occurring with tumor necrosis factor alpha antagonist therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511412996

Infliximab and anterior optic neuropathy: case report and review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511412996

Long-term course of demyelinating neuropathies occurring during tumor necrosis factor-alpha-blocker therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511412996

Neurological adverse events associated with anti-tumor necrosis factor α treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511412996

Adalimumab-associated optic neuritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511412996

Association of anti-tumor necrosis factor therapy with the development of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511412996

Inflammatory demyelinating events following treatment with anti-tumor necrosis factor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511412996

Multiple sclerosis onset during etanercept treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511412996

Optic neuritis associated with adalimumab in the treatment of uveitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511412996

Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511412996

Optic neuritis with concurrent etanercept and isoniazid therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511412996

Infliximab-induced Demyelination Causes Visual Disturbance Mistaken for Recurrence of HLA-B27-related Uveitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511412996

Multiple sclerosis following etanercept treatment for ankylosing spondylitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511412996

Onset of multiple sclerosis associated with anti-TNF therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511412996

Demyelination during anti-tumor necrosis factor alpha therapy with infliximab for Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511412996

Cerebral MRI lesions and anti-tumor necrosis factor-alpha therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511412996

Infliximab-associated retrobulbar optic neuritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511412996

Optic neuritis occurring with anti-tumour necrosis factor alpha therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511412996

Retrobulbar optic neuritis associated with infliximab in a patient with Crohn disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511412996

Bilateral anterior toxic optic neuropathy and the use of infliximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511412996

Acute bilateral phrenic neuropathy following treatment with adalimumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511412996

Guillain-Barre in a patient with ankylosing spondylitis secondary to ulcerative colitis on infliximab therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511412996

Peripheral neuropathy with infliximab therapy in inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511412996

Acute motor and sensory axonal neuropathy and concomitant encephalopathy during tumor necrosis factor-alpha antagonist therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511412996

Myasthenia gravis associated with etanercept therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511412996

Lewis-Sumner syndrome associated with infliximab therapy in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511412996

Etanercept-induced anti-Jo-1-antibody-positive polymyositis in a patient with rheumatoid arthritis: a case report and review of the literature.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511412996

Tumor necrosis factor inhibitor-associated dermatomyositis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511412996

Miller-Fisher syndrome in a patient with rheumatoid arthritis treated with adalimumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511412996

Adalimumab induced mononeuritis multiplex in a patient with refractory rheumatoid arthritis: a case report

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511412996

A case of spontaneously recovering multifocal motor neuropathy with conduction blocks (MMNCB) during anti-TNF alpha therapy for ankylosing spondylitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511412996

Reversible bilateral optic neuritis after Infliximab discontinuation in a patient with Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511412996

The safety profile of anti-tumour necrosis factor therapy in inflammatory bowel disease in clinical practice: analysis of 620 patient-years follow-up.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511412996

A case of progressive multifocal leukoencephalopathy in a patient treated with infliximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511412996

Autoimmune diseases in patients with multiple sclerosis and their first-degree relatives: a nationwide cohort study in Denmark.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511412996

Autoimmune disease in families with multiple sclerosis: a population-based study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511412996

Epidemiology of multiple sclerosis: from risk factors to prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511412996

Tumor necrosis factor and stroke: role of the blood-brain barrier

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511412996

Review: regulation of liver regeneration by pro-inflammatory cytokines

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511412996

Tumor necrosis factor-mediated cell death: to break or to burst, that's the question

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511412996

Cell death in models of spinal cord injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511412996

TNF-alpha receptor fusion protein prevents experimental auto-immune encephalomyelitis and demyelination in Lewis rats: an overview

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511412996

TNF alpha promotes proliferation of oligodendrocyte progenitors and remyelination.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511412996

Positive and negative implications of tumor necrosis factor neutralization for the pathogenesis of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511412996

21 January 2018

Anti-TNF-induced lupus

1 reference

https://api.crossref.org/works/10.1177%2F1352458511412996

Autoantibody production in anti-TNF-alpha-treated patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511412996

Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor alpha: findings in open-label and randomized placebo-controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511412996

Dendritic cells and cytokines in human inflammatory and autoimmune diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511412996

Activation of the human immature natural killer cell subset by IL-12 and its regulation by endogenous TNF-alpha and IFN-gamma secretion

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511412996

21 January 2018

Identifiers

DOI

10.1177/1352458511412996

1 reference

25 August 2017

1 reference